z-logo
Premium
Design and Efficient Synthesis of RalA Inhibitors Containing the Dihydro‐α‐carboline Scaffold
Author(s) -
Leng HaiJun,
Wang YuTing,
He XiangHong,
Xia HouLin,
Xu PengShuai,
Xiang Peng,
He QingQing,
Zhan Gu,
Huang Wei
Publication year - 2021
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202000722
Subject(s) - chemistry , stereochemistry , apoptosis , a549 cell , docking (animal) , microbiology and biotechnology , biochemistry , biology , medicine , nursing
Ras‐related protein RalA is a member of the Ras small GTPases superfamily. Its activation plays an important role in regulating tumor initiation, invasion, migration, and metastasis. In this study, we designed a new type of RalA inhibitor containing a dihydro‐α‐carboline scaffold. The structurally new dihydro‐α‐carboline derivatives could be efficiently synthesized in good yields through a newly developed three‐component [3+2+1] cyclization reaction. Evaluation of the biological activity showed that some of the dihydro‐α‐carboline derivatives can inhibit RalA/B and proliferative activities of NSCLC cell lines. The 4‐(pyridin‐3‐yl)‐dihydro‐α‐carboline compound ( 3 o ) was found to be the most potent derivative, with IC 50 values of 0.43±0.03, 0.64±0.07, 0.93±0.10, and 1.54±0.15 μM against A549, H1299, H460, and H1975 cells, respectively. Mechanism investigation suggested that 3 o inhibits the RalA/B activation of A549, down‐regulates Bcl‐2, stimulates cytochrome c and PARP cleavage, and induces cell apoptosis. A molecular docking study revealed that 3 o can form stable hydrogen bonds with residues of RalA. Moreover, amide‐π and alkyl‐π interactions also contributed to the affinity between 3 o and RalA.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom